We use privacy-friendly analytics. Read our privacy policy.

Compound Profile

Galantamine

Galantamine is best framed as a conservative research profile with mechanistic evidence and a focus on Cognition.

Use extra caution — Nausea, vomiting, bradycardia; caution with cardiac conditions. Details

Last reviewed: •1 source citedReport a correctionProfile-wide ·D Preliminary
Galantamine monograph visual
Generated profile category visual

At a glance

From this profile's structured data
Evidence
Grade D
Safety
Nausea, vomiting, bradycardia; caution with cardiac conditions.
Profile context
acetylcholinesterase, nicotinic receptors
Next steps

Continue reading

Quick stats

Evidence level
Preliminary evidence
Typical onset
Varies by prep
Safety rating
Use extra caution: Use caution
Best for
Acetylcholinesterase, Nicotinic Receptors
Avoid / review if
Caution When Combined With Other Drugs That Lower Heart Rate, Contraindicated With Known Hypersensitivity To Galantamine.

Safety

Safety & Cautions

Nausea, vomiting, bradycardia; caution with cardiac conditions.

High caution

Caution level: High. Multiple caution categories apply, or the record uses avoid/contraindication language.

Evidence Summary

Profile-wide ·D Preliminary

Evidence lens

Early signal that needs stronger human replication before practical claims.

PreliminaryPreliminary evidence

Human clinical evidence: Present in source signals

Mechanistic / preclinical: Mechanism mapped — Neurotransmitter Modulation · Cholinergic

Research maturity: Preliminary research — Early findings are not treated as established consumer benefit.

Safety boundary: Safety note available — Nausea, vomiting, bradycardia; caution with cardiac conditions.

This profile cites 1 human study.

Evidence Strength

Confidence estimate based on the design quality and consistency of published clinical trials.

Preliminary evidence

Galantamine has a preliminary evidence rating.

NootropicFocus
Citation density
0.5
Sources
1
Effects
2
Research recency
Mixed recency
Evidence Grade

Grade D: Preliminary / Theoretical Evidence

Evaluation of methodological rigor, population reach, and evidence alignment.

Design Match
Randomized controlled trial
Risk of Bias
Low
Consistency
Not assessed
Strongest recorded design is a randomized controlled trial, drawn from 2 recorded studies, 2 in people.
How evidence grades work

Each grade reflects the strength and consistency of published human evidence — not marketing claims. Grades are based on study count, design quality, effect size, consistency, and recency.

Strong
Multiple RCTs, consistent direction, adequate effect size
Moderate
Some RCTs or consistent observational data in humans
Preliminary / Mixed
Animal or in-vitro only, or conflicting human data
Traditional / Theoretical
Traditional use only; no controlled human trials
Clinical Study Summaries (1)1 human evidence source · 1 human trial · ~636 participants across 1 human evidence source with reported N · Consistency not yet classifiable

What the evidence actually shows

This table contains 1 structured source, including 1 human evidence source; 1 is a human trial. Across 1 human evidence source with a reported sample size, the approximate participant total is 636; overlapping publications may include some of the same people.

StudyDesignNDoseDurationPopulationOutcomeResult & magnitudeSource

Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group

PubMed · Neurology · 2000

Background
Randomized controlled trial

Randomly assigns participants to interventions or controls, reducing many sources of bias when the trial is conducted well.

n=636—————PubMed →

How Galantamine Works

Simplified mechanism pathway based on preclinical and pharmacological evidence. Does not confirm clinical efficacy.

Mechanism Pathway — How Galantamine Works

How Galantamine WorksGalantamine acts on biological target pathways via neurotransmitter (modulation), leading to acetylcholinesterase.GalantamineBiological TargetBiological pathwayNeurotransmitterModulationAcetylcholinesteraseObservable outcomeAcetylcholineModulation
CompoundTarget / ReceptorMechanismEffect / Outcome

Dosing

Common form
prescription tablet
No standardized dose
Our source data records the usual product form for this ingredient but no studied dose. Preparations differ widely, so follow the standardization on the product you actually have and speak to a clinician before starting.
Mechanisms & biological pathways

Preclinical mechanism details from scientific profiles; these represent plausible pathways but do not guarantee clinical efficacy in humans.

  • Neurotransmitter Modulation
  • Cholinergic

Guides that use Galantamine

Continue exploring

Related research paths

Compare & Sourcing

Compare side-by-side tradeoffs or verify active marker guidelines.

Free safety checklist

Get the Galantamine evidence notes

Occasional research updates, safety context, and product-quality checks for supplement decisions.

We use your email to send the checklist and occasional evidence-first supplement updates. Unsubscribe anytime. Privacy policy.

Safety first · Harm reduction

This information is educational and not medical advice. Start low, avoid risky combinations, and consult a licensed clinician before making health decisions—especially if you use medications, have diagnosed conditions, or are pregnant/breastfeeding.

Learn how we evaluate confidence, safety, and intensity on the methodology page.

Editorial Review

Checked against primary sources, cited evidence, and contraindication language before publication. Evidence claims, safety language, and affiliate modules are reviewed independently. Not personal medical advice.

Editorial Standards →

Help improve this profile

Was this useful for your research?

These controls record only the page and the structured choice you make when analytics consent is enabled. Please don’t include personal medical information in research requests.

Was this evidence summary clear?

Did you find what you were researching?